|本期目录/Table of Contents|

[1]张群燕综述,郭郡浩,蔡辉审校.肿瘤坏死因子受体相关因子6在NF-κB炎症通路中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2017,19(04):390-394.[doi:10.3969/j.issn.1672-271X.2017.04.014]
点击复制

肿瘤坏死因子受体相关因子6在NF-κB炎症通路中的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年04期
页码:
390-394
栏目:
综述
出版日期:
2017-08-10

文章信息/Info

Title:
-
作者:
张群燕综述; 郭郡浩; 蔡辉审校
作者单位：210002南京，南京军区南京总医院中西医结合科
Author(s):
-
关键词:
肿瘤坏死因子受体相关因子6; NF-κB; CD40; 炎症
Keywords:
-
分类号:
R364.7
DOI:
10.3969/j.issn.1672-271X.2017.04.014
文献标志码:
A
摘要:
肿瘤坏死因子受体相关因子6（tumor necrosis factor receptor-associated factor，TRAF6）既可与肿瘤坏死因子受体（TNFR）超家族结合，又可与白细胞介素-1受体/Toll样受体（IL-1R/TLR）超家族相互作用来传递胞外信号的一种胞内接头蛋白，在炎症反应、免疫应答、骨代谢中发挥着重要作用。文章就TRAF6的蛋白结构、核因子-κB炎症通路以及与炎症疾病和临床应用等方面进行综述。
Abstract:
-

参考文献/References:

[1]Xie P. TRAF molecules in cell signaling and in human diseases[J]. J Mol Signal, 2013, 8(1):7.
[2］Zotti T, Vito P. The seventh ring: exploring TRAF7 functions[J]. J Cell Physiol 2012, 227, 1280-1284.
[3］Wang Y, Zhang P, Liu Y, et al. TRAF-mediated regulation of immune and inflammatory responses[J]. Sci China Life Sci, 2010, 53:159-168.
[4］Ishida T, Mizushima S, Azuma S, et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region[J]. J Biol Chem, 1996, 15,271(46):28745-28748.
[5］Ye H, Arron JR, Lamothe B, et al. Distinct molecular mechanism for initiating TRAF6 signaling[J]. Nature, 2002, 418(6896):443-447.
[6］Chung JY, Lu M, Yin Q, et al. Molecular basis for the unique specificity of TRAF6[J]. Adv Exp Med Biol, 2007, 597:122-130.
[7］Lowe EL, Doherty TM, Karahashi H, et al. Ubiquitination and de-ubiquitination: role in regulation of signaling by Toll-like receptors[J]. J Endotoxin Res, 2006,12(6):337-345.
[8］Sato S, Sanjo H, Takeda K, et al. Essential function for the kinase TAKl in innate and adaptive immune responses [J]. Nat Immunol, 2005, 6(11): 1087-1095.
[9］Verstak B, Nagpal K, Bottomley SP, et al. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses[J]. J Biol Chem, 2009, 284(36):24192-24203.
[10］Chatzigeorgiou A, Seijkens T, Zarzycka B, et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance [J]. Proc Natl Acad Sci USA, 2014, 111(7):2686-2691.
[11］Zarzycka B, Seijkens T, Nabuurs SB, et al. Discovery of small molecule CD40-TRAF6 inhibitors[J]. J Chem Inf Model, 2015, 55(2):294-307.
[12］Kobayashi T, Walsh PT, Walsh MC, et al. TRAF6 Is a Critical Factor for Dendritic Cell Maturation and Development[J]. Immunity, 2003, 19(3):353-363.
[13］Iwata S, Yamaoka K, Niiro H, et al. Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation[J]. J Allergy Clin Immunol, 2012, 129(6):1594-1601.
[14］Rowland SL, Tremblay MM, Ellison JM, et al. A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling[J]. J lmmunol, 2007, 179(7): 4645-4653.
[15］Cejas PJ, Walsh MC, Pearce EL, et al. TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2[J]. Blood, 2010, 115(23):4750-4757.
[16］Muto G, Kotani H, Kondo T, et al. TRAF6 is essential for maintenance of regulatory T cells that suppress Th2 type autoimmunity[J]. PLoS One, 2013, 8(9):e74639.
[17］Leo E, Welsh K, Matsuzawa S, et al. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation[J]. J Biol Chem, 1999, 274(32):22414-22422.
[18］Zhang W, Zhang X, Wu Xl, et al. Competition between TRAF2 and TRAF6 Regulates NF-κB Activation in Human B Lymphocytes[J]. Chin Med Sci J, 2010, 25(1):1-12.
[19］Namjou B, Choi CB, Harley IT, et al. Evaluation of TRAF6 in a large multiancestral lupus cohort[J]. Arthritis Rheum, 2012, 64:1960-1969.
[20］刘曦, 许菁, 胡成栋, 等. Toll样受体信号传导通路下游分子单核苷酸多态性与类风湿关节炎易感基因的关联[J]. 中华风湿病学杂志, 2013, 17(2): 76-79.
[21]Zhu LJ, Yang TC, Wu Q. Tumor necrosis factor receptor-associated factor (TRAF) 6 inhibition mitigates the pro-inflammatory roles and proliferation of rheumatoid arthritis fibroblast-like synoviocytes[J]. Cytokine, 2017, 93:26-33.
[22]朱浪静, 欧阳霞, 郑东辉, 等. 类风湿关节炎患者滑膜TRAF6表达与血清骨代谢标志物的相关性[J]. 中华医学杂志, 2014, 94(21): 1643-1646.
[23]Chen J, Wu X, Shao B, et al. Increased expression of TNF receptor-associated factor 6 after rat traumatic brain injury[J]. Cell Mol Neurobiol, 2011, 31:269-275.
[24]Donners MM, Beckers L, Lievens D, et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling[J]. Blood, 2008, 111(9):4596-4604.
[25]Zhang L, Wang T, Lu Y, et al. Tumor Necrosis Factor Receptor-associated Factor 6 Plays a Role in the Inflammatory Responses of Human Periodontal Ligament Fibroblasts to Enterococcus faecalis[J]. J Endod, 2015, 41(12):1997-2001.
[26]徐利东, 李卫星, 李霞, 等. 脂多糖介导的人牙周膜成纤维细胞损伤过程中TRAF6蛋白表达的研究[J]. 中国药物与临床, 2008, 8(3): 168-170.
[27]Riba M, Garcia Manteiga JM, Bonjak B, et al. Revealing the acute asthma ignorome: characterization and validation of uninvestigated gene networks[J]. Sci Rep, 2016, 21(6): 24647.
[28]Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperre-sponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system[J]. Int Immunol,2008,20(6):791-800.
[29]Wu H, Li XM, Wang JR, et al. NUR77 exerts a protective effect against inflammatory bowel disease by negatively regulating the TRAF6/TLR-IL-1R signalling axis[J]. J Pathol, 2016, 238(3):457-469.
[30]Shen J, Qiao Y,Ran Z, et al. Different activation of TRAF4 and TRAF6 in inflammatory bowel disease[J]. Mediators Inflamm, 2013, 2013:647936.
[31]Guo C, Zhang L, Nie L, et al. Association of polymorphisms in the MyD88, IRAK4 and TRAF6 genes and susceptibility to type 2 diabetes mellitus and diabetic nephropathy in a southern Han Chinese population[J]. Mol Cell Endocrinol, 2016,5(429):114-119.
[32]Habibi F, Ghadiri Soufi F, Ghiasi R, et al. Alteration in Inflammation-related miR-146a Expression in NF-KB Signaling Pathway in Diabetic Rat Hippocampus[J]. Adv Pharm Bull, 2016, 6(1):99-103.
[33]赵思嘉, 许蔚起, 刘娜, 等. MiR-146a通过抑制TRAF6减轻自身免疫性心肌炎大鼠心脏炎症并改善其心功能[J]. 中国分子心脏病学杂志, 2015,1： 1202-1205.
[34]何孝亮, 李向培, 陶金辉, 等. miR-146a、TRAF6、IRAK-1在强直性脊柱炎患者外周血单个核细胞中的表达[J]. 中华风湿病学杂志, 2012, 16: 57.
[35]Chen F, Du Y, Zhang Z, et al. Syntenin negatively regulates TRAF6-mediated IL-1R/TLR4 signaling[J]. Cell Signal, 2008, 20(4):666-674.
[36]Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploin sufficiency cause an early-onset autoinflammatory disease[J]. Nat Genet, 2016, 48(1):67-73.
[37]Lamothe B, Besse A, Campos AD, et al. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation[J]. J Biol Chem, 2007, 282(6):4102-4112.
[38]West C, McDermott M. Effects of MicroRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF-κB signalling pathway[J]. Biosci Rep,2017. pii: BSR20170180. [Epub ahead of print].
[39]Hajivalili M, Pourgholi F, Majidi J, et al. G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146aindependent manner[J]. Cell Mol Biol (Noisy-le-grand), 2016, 62(4):1-5.
[40]Walsh MC, Kim GK, Maurizio PL, et al. TRAF6 autoubiquitination-independent activation of the NF kappaB and MAPK pathways in response to IL-1 and RANKL[J]. PLoS One, 2008, 3(12):e4064.

相似文献/References:

备注/Memo

备注/Memo:
基金项目：南京军区南京总医院科研基金（2016040）
更新日期/Last Update: 2017-07-20